New signature predicts MBL-to-CLL progression
In this issue of Blood, Abdelbaky and colleagues report the development of a combined epigenetic and immunogenetic signature to study individuals with high
In this issue of Blood, Abdelbaky and colleagues report the development of a combined epigenetic and immunogenetic signature to study individuals with high
The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines…
A large panel of patient-derived xenograft models of small cell lung cancer reveal that extrachromosomal amplifications of MYC family genes arise after relapse to drive…
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Data from the phase 3 INAVO120 trial support the breakthrough therapy designation granted by the FDA to inavolisib, palbociclib, and fulvestrant for the treatment of…
Abstract. Over the past decade, studies have increasingly shed light on a reciprocal relationship between cellular metabolism and cell fate, meaning that a cell’s lineage…
0:15 – Meeting Begins3:10 – Opening Keynote from Namandjé Bumpus, U.S. FDA and Peter Marks, CBER, U.S. FDA28:42 – The Evolution of Cell and Gene…
Hundreds of guests gathered to raise funds and celebrate the Foundation’s programs
Discover what causes cancers of the skin; learn the signs & symptoms that you should never ignore. Skin cancer information you can trust.
Journal of Neuro-Oncology – Meningiomas with bone involvement account for 4.5–17% of all intracranial meningiomas. Little is known about whether these meningiomas (WHO grade I)…
During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article…